Artio Medical adds $28M in oversubscribed Series A

2022-06-17

Prairie Village, Kansas-based Artio Medical’s added $28 million in oversubscribed Series A2 and Series A3 financings brings the company’s total amount raised in the round to $74 million. According to a news release, Artio Medical plans to use the funds to support its U.S. commercialization efforts for its recently FDA-cleared Solus Gold embolization device, as well as to accelerate the development of its portfolio of products and expand its engineering and manufacturing capabilities. The company currently has 10 products under development for the peripheral vascular market, including Solus Gold and Solus Flex, both of which are embolization devices for peripheral vessel occlusion. It is also working on the Amplifi vein dilation system for preparing hemodialysis patients for successful arteriovenous fistula vascular access site creation. Artio Medical also has four products for the neurovascular market under development, including its Endura embolization system with a detachable balloon and coils for treating saccular brain aneurysms. “We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” Artio Medical VP of Finance and Business Operations Joseph McConnell said in the news release. “We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people. This new capital will help Artio expand our team and scale our operations to deliver on that mission.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构